Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination

Myojin, Yuta; Hikita, Hayato; Tahata, Yuki; Fukumoto, Kenji; Kato, Seiya; Sasaki, Yoichi; Kumazaki, Shusuke; Tsuchiya, Atsunori; Enomoto, Masaru; Miki, Daiki; Yatsuhashi, Hiroshi; Kuroda, Hidekatsu; Uchida, Yoshihito; Yoshiji, Hitoshi; Yamashita, Taro; Mawatari, Seiichi; Tamaki, Nobuharu; Miyaaki, Hisamitsu; Asahina, Yasuhiro; Suda, Goki; Matsuura, Kentaro; Nakamoto, Yasunari; Hiasa, Yoichi; Takami, Taro; Shirai, Kumiko; Maesaka, Kazuki; Murai, Kazuhiro; Makino, Yuki; Saito, Yoshinobu; Kodama, Takahiro; Tatsumi, Tomohide; Takehara, Tetsuo

doi:https://doi.org/10.1111/hepr.70041

Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination

Myojin, Yuta; Hikita, Hayato; Tahata, Yuki et al.

Hepatology Research, 2025

Number of Access:37（2025-12-05 11:18 Counts）

Identifier to cite or link to this item: https://hdl.handle.net/11094/102970

Link to primary information

File	Format	Terms of use	Size	Views	Date.Available	Description	information
HepatolRes	pdf	None	2.24 MB	13	2025.10.31

Creative Commons : Attribution - NonCommercial - NoDerivatives

Item Information

Output File Export EndNote Basic Export Mendeley

Title	Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination
Creator	NRID 1000020838817 1000020838817 ORCID 0000-0003-0360-9703 0000-0003-0360-9703 researchmap permalink yumyojin yumyojin Scopus Author ID 57211278135 57211278135 CreatorName Myojin, Yuta
	NRID 1000020623044 1000020623044 ORCID 0000-0003-2488-7315 0000-0003-2488-7315 researchmap permalink hikitahayato hikitahayato Scopus Author ID 23667454900 23667454900 CreatorName Hikita, Hayato
	NRID 1000000838047 1000000838047 ORCID 0000-0002-9116-7054 0000-0002-9116-7054 researchmap permalink yuki.tahata yuki.tahata Scopus Author ID 56755390400 56755390400 CreatorName Tahata, Yuki
	NRID 1000061011515 1000061011515 ORCID 0000-0002-8437-1153 0000-0002-8437-1153 researchmap permalink k.fukumoto k.fukumoto Scopus Author ID 57201500290 57201500290 CreatorName Fukumoto, Kenji
	CreatorName Kato, Seiya
	CreatorName Sasaki, Yoichi
	CreatorName Kumazaki, Shusuke
	NRID 1000070464005 1000070464005 CreatorName Tsuchiya, Atsunori
	NRID 1000020423874 1000020423874 CreatorName Enomoto, Masaru
	NRID 1000010584592 1000010584592 CreatorName Miki, Daiki
	NRID 1000050360855 1000050360855 CreatorName Yatsuhashi, Hiroshi
	NRID 1000070382596 1000070382596 CreatorName Kuroda, Hidekatsu
	CreatorName Uchida, Yoshihito
	NRID 1000040336855 1000040336855 CreatorName Yoshiji, Hitoshi
	NRID 1000090377432 1000090377432 CreatorName Yamashita, Taro
	NRID 1000050735339 1000050735339 CreatorName Mawatari, Seiichi
	CreatorName Tamaki, Nobuharu
	NRID 1000020437891 1000020437891 CreatorName Miyaaki, Hisamitsu
	NRID 1000000422692 1000000422692 CreatorName Asahina, Yasuhiro
	NRID 1000020447460 1000020447460 CreatorName Suda, Goki
	NRID 1000030580576 1000030580576 CreatorName Matsuura, Kentaro
	NRID 1000040293352 1000040293352 CreatorName Nakamoto, Yasunari
	NRID 1000070314961 1000070314961 CreatorName Hiasa, Yoichi
	NRID 1000060511251 1000060511251 CreatorName Takami, Taro
	NRID 1000020992267 1000020992267 researchmap permalink u987841f u987841f CreatorName Shirai, Kumiko
	NRID 1000080974857 1000080974857 ORCID 0009-0007-5642-9470 0009-0007-5642-9470 researchmap permalink maesaka maesaka Scopus Author ID 57205239322 57205239322 CreatorName Maesaka, Kazuki
	NRID 1000050867314 1000050867314 ORCID 0000-0001-8634-2922 0000-0001-8634-2922 researchmap permalink murai_kazuhiro murai_kazuhiro Scopus Author ID 57202460806 57202460806 CreatorName Murai, Kazuhiro
	NRID 1000060771334 1000060771334 researchmap permalink yuki-makino yuki-makino Scopus Author ID 41561612200 41561612200 CreatorName Makino, Yuki
	NRID 1000060814598 1000060814598 ORCID 0000-0002-0624-0449 0000-0002-0624-0449 researchmap permalink saito_yoshinobu saito_yoshinobu Scopus Author ID 55912459300 55912459300 CreatorName Saito, Yoshinobu
	NRID 1000010623275 1000010623275 ORCID 0000-0002-6250-1324 0000-0002-6250-1324 researchmap permalink takahirokodama takahirokodama Scopus Author ID 35193885800 35193885800 CreatorName Kodama, Takahiro
	NRID 1000020397699 1000020397699 researchmap permalink read0140669 read0140669 Scopus Author ID 7202112131 7202112131 CreatorName Tatsumi, Tomohide
	NRID 1000070335355 1000070335355 CreatorName Takehara, Tetsuo
Subject	decompensated cirrhosis
	HCV
	liver cancer
Description	Myojin Y., Hikita H., Tahata Y., et al. Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination. Hepatology Research (2025); https://doi.org/10.1111/hepr.70041.
Abstract	Background and Aims: Although direct-acting antivirals (DAAs) achieve high sustained virologic response (SVR) rates, the long-term outcomes of patients with hepatitis C virus (HCV)-related cirrhosis remain variable. Growth differentiation factor 15 (GDF15), a stress-induced cytokine, has emerged as a potential biomarker for liver disease progression. This study aimed to evaluate the prognostic value of serum GDF15 levels in predicting hepatocellular carcinoma (HCC), hepatic decompensation, and mortality in patients with HCV-related cirrhosis. Methods: We retrospectively analyzed 196 patients with HCV-related cirrhosis who achieved SVR at 18 Japanese institutions. Serum GDF15 levels were measured at baseline (BL) and 24 weeks posttreatment (p24w). A previously validated cutoff of 1.75 ng/mL was applied. The clinical outcomes included HCC occurrence, hepatic decompensation, and all-cause mortality. Results: During a median follow-up of 46.2 months, 75 patients developed HCC, 28 experienced hepatic decompensation, and 25 died. Hepatic decompensation occurred significantly less frequently in the BL GDF15-low group. Importantly, no deaths occurred in the GDF15-low group, whereas the 5-year survival rate in the GDF15-high group was 71.7%. Similar trends were observed for GDF15 levels at p24w. In the overall cohort, GDF15 was not significantly associated with incident HCC; among HCC-naïve patients, a nonsignificant trend toward lower 3-year HCC incidence was observed in the GDF15-low group. Conclusions: Serum GDF15 is a promising prognostic biomarker for post-SVR outcomes in patients with HCV-related cirrhosis. Its ability to predict decompensation and mortality through a validated cutoff supports its use for risk stratification and long-term management in patients with chronic liver disease.
Publisher	John Wiley and Sons Inc
Source Title	Hepatology Research
Date of Issued	2025-09-18
Language	English
Handle URL	https://hdl.handle.net/11094/102970
PISSN	13866346
eISSN	1872034X
Relation.isIdenticalTo	DOI (Publisher Version) https://doi.org/10.1111/hepr.70041
Access Rights	open access
CopyRight	This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
CopyRight	© 2025 The Author(s). Hepatology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Hepatology.
oaire:version	Version of Record
Category	学術雑誌論文 Journal Article

Resource Type	journal article
Local Type	Journal Article
DCMI Type	Text
DCTERMS.bibliographicCitation	Hepatology Research. 2025
DC.title	Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination
DC.creator	Myojin, Yuta
	Hikita, Hayato
	Tahata, Yuki
	Fukumoto, Kenji
	Kato, Seiya
	Sasaki, Yoichi
	Kumazaki, Shusuke
	Tsuchiya, Atsunori
	Enomoto, Masaru
	Miki, Daiki
	Yatsuhashi, Hiroshi
	Kuroda, Hidekatsu
	Uchida, Yoshihito
	Yoshiji, Hitoshi
	Yamashita, Taro
	Mawatari, Seiichi
	Tamaki, Nobuharu
	Miyaaki, Hisamitsu
	Asahina, Yasuhiro
	Suda, Goki
	Matsuura, Kentaro
	Nakamoto, Yasunari
	Hiasa, Yoichi
	Takami, Taro
	Shirai, Kumiko
	Maesaka, Kazuki
	Murai, Kazuhiro
	Makino, Yuki
	Saito, Yoshinobu
	Kodama, Takahiro
	Tatsumi, Tomohide
	Takehara, Tetsuo
DC.publisher	John Wiley and Sons Inc
DC.language' scheme='DCTERMS.RFC1766	English
DC.type' scheme='DCTERMS.DCMIType	Text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2025-09-18
DC.identifier	https://doi.org/10.1111/hepr.70041
DC.subject	decompensated cirrhosis
	HCV
	liver cancer
DC.description	Myojin Y., Hikita H., Tahata Y., et al. Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination. Hepatology Research (2025); https://doi.org/10.1111/hepr.70041.
DCTERMS.abstract	Background and Aims: Although direct-acting antivirals (DAAs) achieve high sustained virologic response (SVR) rates, the long-term outcomes of patients with hepatitis C virus (HCV)-related cirrhosis remain variable. Growth differentiation factor 15 (GDF15), a stress-induced cytokine, has emerged as a potential biomarker for liver disease progression. This study aimed to evaluate the prognostic value of serum GDF15 levels in predicting hepatocellular carcinoma (HCC), hepatic decompensation, and mortality in patients with HCV-related cirrhosis. Methods: We retrospectively analyzed 196 patients with HCV-related cirrhosis who achieved SVR at 18 Japanese institutions. Serum GDF15 levels were measured at baseline (BL) and 24 weeks posttreatment (p24w). A previously validated cutoff of 1.75 ng/mL was applied. The clinical outcomes included HCC occurrence, hepatic decompensation, and all-cause mortality. Results: During a median follow-up of 46.2 months, 75 patients developed HCC, 28 experienced hepatic decompensation, and 25 died. Hepatic decompensation occurred significantly less frequently in the BL GDF15-low group. Importantly, no deaths occurred in the GDF15-low group, whereas the 5-year survival rate in the GDF15-high group was 71.7%. Similar trends were observed for GDF15 levels at p24w. In the overall cohort, GDF15 was not significantly associated with incident HCC; among HCC-naïve patients, a nonsignificant trend toward lower 3-year HCC incidence was observed in the GDF15-low group. Conclusions: Serum GDF15 is a promising prognostic biomarker for post-SVR outcomes in patients with HCV-related cirrhosis. Its ability to predict decompensation and mortality through a validated cutoff supports its use for risk stratification and long-term management in patients with chronic liver disease.
DC.rights	This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
DC.rights	© 2025 The Author(s). Hepatology Research published by John Wiley & Sons Australia, Ltd on behalf of Japan Society of Hepatology.
DC.format	102970
citation_title	Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination
citation_author	Myojin, Yuta
	Hikita, Hayato
	Tahata, Yuki
	Fukumoto, Kenji
	Kato, Seiya
	Sasaki, Yoichi
	Kumazaki, Shusuke
	Tsuchiya, Atsunori
	Enomoto, Masaru
	Miki, Daiki
	Yatsuhashi, Hiroshi
	Kuroda, Hidekatsu
	Uchida, Yoshihito
	Yoshiji, Hitoshi
	Yamashita, Taro
	Mawatari, Seiichi
	Tamaki, Nobuharu
	Miyaaki, Hisamitsu
	Asahina, Yasuhiro
	Suda, Goki
	Matsuura, Kentaro
	Nakamoto, Yasunari
	Hiasa, Yoichi
	Takami, Taro
	Shirai, Kumiko
	Maesaka, Kazuki
	Murai, Kazuhiro
	Makino, Yuki
	Saito, Yoshinobu
	Kodama, Takahiro
	Tatsumi, Tomohide
	Takehara, Tetsuo
citation_publisher	John Wiley and Sons Inc
citation_language	English
citation_date	2025-09-18
citation_journal_title	Hepatology Research
citation_doi	https://doi.org/10.1111/hepr.70041
citation_public_url	https://hdl.handle.net/11094/102970

Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination

Link to primary information

Item Information

Show details